US8067055B2ActiveUtilityA1
Drug-delivery endovascular stent and method of use
Est. expiryOct 20, 2026(~0.3 yrs left)· nominal 20-yr term from priority
A61L 2300/60A61F 2/0077A61F 2/915A61L 31/022A61F 2002/91541A61F 2/91A61F 2250/0067A61L 2300/416A61L 31/16A61F 2/82A61L 27/54A61F 2/07
88
PatentIndex Score
14
Cited by
138
References
8
Claims
Abstract
A radially expandable, endovascular stent designed for placement at a site of vascular injury, for inhibiting restenosis at the site, a method of using, and a method of making the stent. The stent includes a radially expandable body formed of one or more metallic filaments where at least one surface of the filaments has a roughened or abraded surface. The stent may include a therapeutic agent on the abraded surface.
Claims
exact text as granted — not AI-modified1. A method of producing a radially expandable, endovascular stent designed for placement at a site of vascular injury, for inhibiting restenosis at the site, comprising positioning the stent onto a mandrel covered with an exterior mask of hydrocarbon film; crimping the stent into the mask; ensuring that at least a portion of the stent that is not to be abraded is covered by the mask; texturing at least a portion of the stent; and applying a therapeutic agent to at least a portion of the abraded, roughened, or textured portion of the stent.
2. The method according to claim 1 , wherein said applying a therapeutic agent comprises infusing the agent into a substratum formed in the abraded, roughened, or textured surface.
3. The method according to claim 1 , further comprising removing said mask after said texturing.
4. The method according to claim 1 , wherein said texturing comprises microblasting at least a portion of the stent.
5. The method according to claim 1 , wherein said texturing comprises shot peening at least a portion of the stent.
6. The method according to claim 1 , wherein said texturing comprises differentially compressing the stent.
7. The method according to claim 1 , further comprising passivating at least a portion of the stent after said texturing.
8. The method according to claim 1 , wherein said therapeutic agent comprises an anti-restenosis drug.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.